KaloCyte

Executive Summary

KaloCyte is a preclinical-stage biotechnology company developing ErythroMer™, a dried, bio-inspired artificial red blood cell substitute designed to address life-threatening blood loss in settings where traditional stored red blood cells are unavailable or in short supply. The product aims to provide a shelf-stable, universal blood substitute for trauma, emergency medicine, and military applications. Founded in 2017 and headquartered in Baltimore, Maryland, KaloCyte targets a critical unmet need in global health, particularly in austere environments and low-resource settings. The company has not yet disclosed total funding or valuation, but its innovative platform could transform transfusion medicine if successfully developed. As a preclinical entity, KaloCyte faces significant technical and regulatory hurdles, including demonstrating efficacy and safety in animal models and eventually humans. The artificial blood substitute market is challenging, with many past failures, but ErythroMer's bio-inspired design may offer advantages. Key upcoming milestones include completing IND-enabling studies, initiating first-in-human trials, and securing additional financing. Conviction in the company remains moderate given the early stage and high risk, but the potential impact justifies attention from investors interested in revolutionary medical technologies.

Upcoming Catalysts (preview)

• Q3 2026Series A/B financing round60% success
• Q4 2026IND-enabling study results in animal models50% success
• Q2 2026Partnership or government grant for trauma/military use40% success